We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
HP (HPQ) to Report Q1 Earnings: What's in Store for the Stock?
Read MoreHide Full Article
HP Inc. (HPQ - Free Report) will report first-quarter fiscal 2021 results on Feb 25.
The company estimates non-GAAP earnings to lie between 64 cents and 70 cents. The Zacks Consensus Estimate for quarterly earnings is pinned at 65 cents per share, indicating the bottom line to have been flat year on year. The consensus mark for revenues is pegged at $15.24 billion, suggesting a year-on-year increase of 4.3%.
The company’s earnings surpassed estimates in all of the preceding four quarters, the surprise being 17.4%, on average.
Let’s see how things have shaped up prior to the upcoming announcement.
Factors at Play
HP’s fiscal first-quarter performance is likely to have benefited from solid demand for personal systems, driven by the remote-working and online-learning trends amid the COVID-19 pandemic. Nevertheless, industry-wide CPU and panel-supply constraints might have affected its ability to meet demand.
For the printing segment, HP had earlier projected solid demand for home printers and pricing to be strained due to competition. On the demand front, the company expects commercial print to have been depressed during the quarter under review.
Additionally, adverse foreign-currency fluctuations and macroeconomic woes are the key concerns this earnings season.
What Our Model Says
Our proven model does not predict an earnings beat for HP this time around. The combination of a positive Earnings ESP, and Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold), increases the chances of an earnings beat. But that’s not the case here. You can uncover the best stocks to buy or sell, before they’re reported, with our Earnings ESP Filter.
HP currently carries a Zacks Rank of 2 (Buy) and has an Earnings ESP of 0.00%.
Stocks With Favorable Combinations
Here are some companies, which, per our model, have the right combination of elements to post an earnings beat this quarter:
Autodesk, Inc. (ADSK - Free Report) has an Earnings ESP of +2.29% and carries a Zacks Rank of 3, currently.
Etsy, Inc. (ETSY - Free Report) has an Earnings ESP of +0.75% and currently holds a Zacks Rank of 3.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
Image: Bigstock
HP (HPQ) to Report Q1 Earnings: What's in Store for the Stock?
HP Inc. (HPQ - Free Report) will report first-quarter fiscal 2021 results on Feb 25.
The company estimates non-GAAP earnings to lie between 64 cents and 70 cents. The Zacks Consensus Estimate for quarterly earnings is pinned at 65 cents per share, indicating the bottom line to have been flat year on year. The consensus mark for revenues is pegged at $15.24 billion, suggesting a year-on-year increase of 4.3%.
The company’s earnings surpassed estimates in all of the preceding four quarters, the surprise being 17.4%, on average.
Let’s see how things have shaped up prior to the upcoming announcement.
Factors at Play
HP’s fiscal first-quarter performance is likely to have benefited from solid demand for personal systems, driven by the remote-working and online-learning trends amid the COVID-19 pandemic. Nevertheless, industry-wide CPU and panel-supply constraints might have affected its ability to meet demand.
HP Inc. Price and Consensus
HP Inc. price-consensus-chart | HP Inc. Quote
For the printing segment, HP had earlier projected solid demand for home printers and pricing to be strained due to competition. On the demand front, the company expects commercial print to have been depressed during the quarter under review.
Additionally, adverse foreign-currency fluctuations and macroeconomic woes are the key concerns this earnings season.
What Our Model Says
Our proven model does not predict an earnings beat for HP this time around. The combination of a positive Earnings ESP, and Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold), increases the chances of an earnings beat. But that’s not the case here. You can uncover the best stocks to buy or sell, before they’re reported, with our Earnings ESP Filter.
HP currently carries a Zacks Rank of 2 (Buy) and has an Earnings ESP of 0.00%.
Stocks With Favorable Combinations
Here are some companies, which, per our model, have the right combination of elements to post an earnings beat this quarter:
Workday, Inc. (WDAY - Free Report) has an Earnings ESP of +1.21% and carries a Zacks Rank of 2, at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Autodesk, Inc. (ADSK - Free Report) has an Earnings ESP of +2.29% and carries a Zacks Rank of 3, currently.
Etsy, Inc. (ETSY - Free Report) has an Earnings ESP of +0.75% and currently holds a Zacks Rank of 3.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>